Scholar Rock Holding (SRRK) Common Equity (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Common Equity of $276.0 million in Q1 2026, up 12.43% quarter-over-quarter from $245.5 million in Q4 2025, and down 11.63% on a YoY basis from $312.3 million in Q1 2025.
Scholar Rock Holding (SRRK) Common Equity (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Common Equity history runs 10 years deep, the most recent figure standing at $276.0 million for Q1 2026.
- In Q1 2026, Common Equity fell 11.63% year-over-year to $276.0 million; the TTM figure through Mar 2026 stood at $276.0 million (down 11.63% YoY), while the FY2025 annual figure was $245.5 million, down 33.41% from the prior year.
- Common Equity was $276.0 million for Q1 2026 at Scholar Rock Holding, up from $245.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $368.6 million in Q4 2024 to a low of $79.2 million in Q3 2024.
- Historically, Common Equity has averaged $232.6 million across 5 years, with a median of $233.3 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Common Equity slumped 52.77% in 2024, then soared 209.35% in 2025.
- A 5-year view of Common Equity shows it stood at $260.2 million in 2022, then dropped by 13.46% to $225.2 million in 2023, then surged by 63.68% to $368.6 million in 2024, then plunged by 33.41% to $245.5 million in 2025, then rose by 12.43% to $276.0 million in 2026.
- The last three Common Equity figures came in at $276.0 million (Q1 2026), $245.5 million (Q4 2025), and $245.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | 276.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 276.01 Mn |
| Dec 31, 2025 | 245.49 Mn |
| Sep 30, 2025 | 245.00 Mn |
| Jun 30, 2025 | 233.29 Mn |
| Mar 31, 2025 | 312.33 Mn |
| Dec 31, 2024 | 368.63 Mn |
| Sep 30, 2024 | 79.20 Mn |
| Jun 30, 2024 | 133.62 Mn |
| Mar 31, 2024 | 182.77 Mn |
| Dec 31, 2023 | 225.22 Mn |
| Sep 30, 2023 | 167.67 Mn |
| Jun 30, 2023 | 202.50 Mn |
| Mar 31, 2023 | 228.65 Mn |
| Dec 31, 2022 | 260.24 Mn |
| Sep 30, 2022 | 293.27 Mn |
| Jun 30, 2022 | 329.51 Mn |
| Mar 31, 2022 | 171.32 Mn |
| Dec 31, 2021 | 172.07 Mn |
| Sep 30, 2021 | 187.26 Mn |
| Jun 30, 2021 | 216.66 Mn |